Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CI-581-a

Phase 3Small molecule

NNew York State Psychiatric Institute

CI-581-a is one of 11 small molecule programs targeting TIA. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

10

Competitors

Pipeline

Status by Indication[3][1]

Indication

TIAActive, not recruiting

TIAPhase 3

Active, not recruiting

Competition

Competitive Landscape

14 competitors in TIA

#DrugCompanyPhaseTrials

Taxotere

Venclexta

Calquence

Gazyva

CI-581-a

NNew York State Psychiatric Institute

Sequential

PPeking Union Medical College Hospital

Tegafur-Gimeracil-Oteracil

NNational Taiwan University Hospital

BAY 987519

Apelin

UUniversity of Edinburgh

Standard SPF 4 Sunscreen

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

TIA1 trial

Facilitating Rapid Naltrexone Initiation

Active, not recruiting·NNew York State Psychiatric Institute·Phase 3·NCT03345173·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CI-581-a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CI-581-a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CI-581-a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York State Psychiatric Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNew York State Psychiatric Institute

Related News